Actinogen Medical Ltd has released a press release.
Peer-reviewed clinpharm manuscript published
Filed with ASX ·
6ix hasn’t read this filing yet.
Actinogen Medical Limited on 6ix
Earlier from Actinogen Medical
- ACW December 2024 quarterly activity report & Appendix 4C
- ACW randomizes first US participant in Alzheimers trial
- Actinogen receives $9.0 million R&D tax incentive rebate
- ACW September 2024 quarterly activity report & Appendix 4C
- $3.0 million share purchase plan closes 1.3x oversubscribed
Later from Actinogen Medical
- ACW HY25 results Advancing to latestage clinical development
- ACW conducts Type C meeting with FDA regarding depression
- Actinogen March 2025 quarterly activity report & Appendix 4C
- Actinogen provides pivotal Alzheimer’s trial enrolment update and other business news
- ACW 100th AD trial participant & interim analysis timeline
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical